Results 41 to 50 of about 99,677 (264)

Case Report: Safety and Efficacy of Tocilizumab in a Patient with Rheumatoid Arthritis and Chronic Hepatitis C

Case Reports in Medicine, 2012
Tocilizumab is a monoclonal humanized anti-IL-6-receptor antibody used for the treatment of rheumatoid arthritis. The safety of tocilizumab in HCV patients is an open question. We report on safety and efficacy of tocilizumab in a 71-year-old female with
Filippo Iebba, Fiorella Di Sora, Agapito Tarasi, Wilma Leti, Tatiana Montella, Francesco Montella   +5 more
doaj   +1 more source

A nationwide survey on patient's versus physician's evaluation of biological therapy in rheumatoid arthritis in relation to disease activity and route of administration : the Be-Raise study [PDF]

, 2016
Objectives : Biological treatment of rheumatoid arthritis (RA) is one of the cornerstones of current treatment strategies for the disease. Surprisingly little information exists on whether the route of administration affects patients' treatment ...
Bert Vander Cruyssen, Dirk Elewaut, Herman Mielants, Jan Lenaerts, null null, Patrick Durez, René Westhovens, Sophie De Mits   +7 more
core   +4 more sources

Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab [PDF]

, 2016
Background Treatment response, remission rates and compliance in patients with polyarticular juvenile idiopathic arthritis (polyJIA) treated with adalimumab, etanercept, or tocilizumab were analyzed in clinical practice.
Haas, Johannes-Peter, Horneff, Gerd, Hospach, Anton, Huppertz, Hans-Iko, Klein, Ariane, Klotsche, Jens, Kuemmerle-Deschner, Jasmin, Minden, Kirsten, Weller-Heinemann, Frank   +8 more
core   +4 more sources

Tocilizumab in Coronavirus Disease 2019-Related Critical Illness: A Propensity Matched Analysis

Critical Care Explorations, 2021
Objectives:. The primary objective was to evaluate ICU mortality at 28 days in patients with severe hypoxemic respiratory failure due to coronavirus disease 2019 infection who received tocilizumab. The secondary objectives were to evaluate ICU-, hospital-
Prabalini Rajendram, MD, Gretchen L. Sacha, PharmD, Omar Mehkri, MD, Xiaofeng Wang, PhD, Xiaozhen Han, MS, Vidula Vachharajani, MD, Abhijit Duggal, MD   +6 more
doaj   +1 more source

Targeting inflammation to reduce cardiovascular disease risk: a realistic clinical prospect? [PDF]

, 2017
Data from basic science experiments is overwhelmingly supportive of the causal role of immune-inflammatory response(s) at the core of atherosclerosis, and therefore the theoretical potential to manipulate the inflammatory response to prevent ...
Abbas, Agca, Ait-Oufella, Albert, Alexander, Alexander, Alexander, Alexander, Andersen, Aziz, Babelova, Bellosta, Bevilacqua, Bhaskar, Blom, Boekholdt, Boekholdt, Bostrom, Brånén, Bulgarelli, Bulgarelli, Burke, Cai, Cannon, Casas, Collins, Cronstein, Dahlman-Ghozlan, Danesh, Davenport, Davey Smith, Davidson, DeOliveira, Devlin, Dinarello, Duewell, Duivenvoorden, Eisenhardt, Elango, Elhage, Ettehad, Flood, Fraser, Freigang, Fulgoni, Galkina, Galkina, Garlanda, Grassia, Grassia, Greenberg, Hansson, Hauer, Herder, Holmes, Hu, Huang, Huber, Interleukin 1 Genetics Consortium, Ivandic, Kalliolias, Kaptoge, Kimura, Kinlay, Kirii, Kleinman, Koltsova, Kureishi, Kwak, Lee, Leite, Leite, Lewington, Liao, Libby, Libby, Macritchie, Maddaluno, Maeda, Maffia, Makheja, Margaritis, McInnes, Menu, Micha, Mihaylova, Mira, Mohler, Montezano, Mulhaupt, Murad, Myasoedova, Myung, Nakata, Nicholls, O'Donoghue, Ogdie, Ohta, Pauling, Peters, Qiao, Quarck, Rajamäki, Rastogi, Reiss, Rezaie-Majd, Ridker, Ridker, Rincón, Robertson, Romano, Rosenson, Rosenson, Roubille, Ryan, Rössig, Saeed, Sage, Sarwar, Sattar, Scalia, Schett, Schieffer, Schuett, Serruys, Sever, Sever, Shah, Shaposhnik, Singh, Sirtori, Sniderman, Soedamah-Muthu, Solomon, Southan, Souverein, Sprague, Srikakulapu, Strober, Sukovich, Swerdlow, Swirski, Talmud, Tay, Teng, Thompson, Tits, Toedter, Turunen, Tzellos, Walker, Wang, Wang, Watson, Weintraub, Welsh, Welsh, Welsh, Welsh, Weng, Wensley, White, Wilensky, Willeit, Willis, Wong, Woodward, Xanthoulea, Ye, Ye, Yilmaz, Youssef, Zalewski, Zhao   +173 more
core   +2 more sources

Observational Study of Tocilizumab in Children With Febrile Infection‐Related Epilepsy Syndrome

Annals of Clinical and Translational Neurology
Objective This study aimed to assess the efficacy and safety of using tocilizumab in children with febrile infection‐related epilepsy syndrome (FIRES) and explore tocilizumab‐related changes in interleukin (IL)‐6 levels.
Yushan He, Jie Wu, Chaonan Fan, Zheng Li, Jun Liu, Kechun Li, Quan Wang, Suyun Qian   +7 more
doaj   +1 more source

Real‐World Investigation of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Satralizumab, a monoclonal antibody targeting the interleukin‐6 receptor, has demonstrated efficacy in clinical trials for neuromyelitis optica spectrum disorder (NMOSD). However, its real‐world effectiveness and safety compared to conventional immunosuppressive therapies remain uncertain.
Li‐Tsung Lin, Hui‐An Lin, Sheng‐Feng Lin   +2 more
wiley   +1 more source

Effectiveness and safety of tocilizumab in patients with systemic sclerosis: a propensity score matched controlled observational study of the EUSTAR cohort

RMD Open, 2022
Objectives Tocilizumab showed trends for improving skin fibrosis and prevented progression of lung fibrosis in systemic sclerosis (SSc) in randomised controlled clinical trials.
, Pavel I Novikov, Thierry Martin, Eric Hachulla, Vanessa Smith, Maurizio Cutolo, Yannick Allanore, Camillo Ribi, Oliver Distler, Britta Maurer, Paolo Airo, Cosimo Bruni, Veronica Codullo, Luc Mouthon, Marie Vanthuyne, Elisabetta Zanatta, Simona Rednic, Ulf Müller-Ladner, Nemanja Damjanov, Anna-Maria Hoffmann-Vold, Michele Iudici, Suzana Jordan, Jean Sibilia, Mengtao Li, Roger Hesselstrand, Elise Siegert, László Czirják, Armando Gabrielli, Dominique Farge Bancel, Yolanda Braun-Moscovici, Nicolas Hunzelmann, Raffaele Pellerito, Jörg Henes, Bojana Stamenkovic, Carlo Francesco Selmi, Mohammed Tikly, Merete Engelhart, Valeria Riccieri, Cord Sunderkötter, Francesca Ingegnoli, Francesco Paolo Cantatore, Susanne Ullman, Maria Rosa Pozzi, Piotr Wiland, Juan Jose Alegre-Sancho, Brigitte Krummel-Lorenz, Ellen De Langhe, Branimir Anic, Carolina de Souza Müller, Simon Stebbings, Alessandra Vacca, Lisa Stamp, Kamal Solanki, Douglas Veale, Esthela Loyo, Edoardo Rosato, Cristina-Mihaela Tanaseanu, Rosario Foti, Codrina Ancuta, Ira Litinsky, Lesley Ann Saketkoo, Eduardo Kerzberg, Tim Schmeiser, Piercarlo Sarzi Puttini, Fabio Cacciapaglia, Marie-Elise Truchetet, Muriel Elhai, Juan José Alegre Sancho, Ivan Castellví, Serena Vettori, Vivien M Hsu, Masataka Kuwana, Sule Yavuz, Radim Becvar, Patricia E Carreira, Eugene J Kucharz, Bernard Coleiro, Paul Hasler, Carlos de la Puente, Svetlana Agachi, Thierry Zenone, Francesco Del Galdo, Doron Rimar, Alessandro Giollo, Lidia P Ananieva, Ina Kötter, Mislav Radic, Dominik Majewski, Kristine Herrmann, Goda Seskute, Lorinda S Chung, Laura Belloli, Ulrike Held, FJ López-Longo, Joerg H W Distler, Maria João Salvador, Simon Kuster, Klaus Steigmiller, Ana-Maria Gheorghiu, Katarzyna Romanowska-Prochnicka, Yuichiro Shirai, Chris Denton, Ruxandra M Ionescu, Stefan Heitmann Vera Ortiz-Santamaria, Walid Ahmed Abdel Atty Mohamed, Paloma Garcíadela Peña Lefebvre, Vera Bernardino   +106 more
doaj   +1 more source

Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials. [PDF]

, 2020
BACKGROUND:Siltuximab is recommended by international consensus as a first-line treatment for idiopathic multicentric Castleman disease on the basis of durable efficacy and safety data.
Casper, Corey, Fayad, Luis E, Gibson, Damilola, Kanhai, Karan, Kurzrock, Razelle, van Rhee, Frits, Voorhees, Peter M   +6 more
core  

Castleman disease and lymphocytic interstitial pneumonia: a complex diagnostic and management challenge [PDF]

, 2016
No abstract ...
Bayes, Hannah K., Chalmers, George W., McInnes, Iain B.   +2 more
core   +1 more source